Breast implant with internal flow dampening

Abstract
An implantable prosthesis is provided having a membrane which holds a flowable substance. The membrane is separated into a first chamber and a second chamber with the first and second chambers being fluidly coupled via an orifice. The orifice has a size which may be adjusted by the user after implanting the prosthesis into the patient.
Description
BACKGROUND OF THE INVENTION

The present invention is directed to an implantable prosthesis which may be used anywhere in the body such as the breast.


An implant provides support for the surrounding body tissue and occupies voids created by the removal of tissue to preserve the normal outward appearance and feel of the body. Prosthetic devices have also been used to enhance or augment the appearance of body parts.


Breast prostheses have long been used for breast augmentation and for reconstruction such as following a mastectomy. The prostheses are available in numerous sizes and shapes including teardrop, round and low profile. Usually, breast prostheses are implanted via a small inframammary or pari-aerolar incision into a pocket dissected deep into the patient's own breast tissue in front of the pectoral muscle. In certain situations, the prosthesis may be placed behind the various chest muscles.


Some prosthetic devices have utilized an outer shell or envelope which is filled with a flowable substance such as silicone gel or saline. These prior art devices have tactile properties similar to normal tissue but suffer from certain disadvantages. Saline filled prosthetic devices can lack the proper appearance and tactile properties of normal tissue. Saline displaces relatively quickly and can create a fluid wave in the implant which presents an unnatural look and an audible sound. Saline filled implants also lack form stability which may result in the implant folding over itself or visible wrinkling.


The object of the present invention is to overcome some of the drawbacks of the prior art implants. The object of the present invention is to construct a surgically implantable prosthetic device which may be filled with saline and/or other fluids and which has desirable tactile appearance and other characteristics.


SUMMARY OF THE INVENTION

The implantable prosthesis of the present invention includes a membrane and an open cell structure contained within the membrane. The open cell structure dampens fluid motion within the membrane to reduce some of the problems with prior art devices as described above.


In one aspect of the invention, the implantable prosthesis has an orifice of adjustable size. The orifice provides fluid communication between a first chamber and a second chamber in the membrane. The size of the orifice may be adjusted after implantation of the prosthesis using a control element.


In another aspect of the present invention, an implantable prosthesis is provided which has a tension element extending between two locations on the membrane. The tension on the tension element may be altered before or after introduction of the prosthesis into the patient. The tension element may extend through a seal which permits tensioning of the tension element while preventing the flowable substance from leaking out of the membrane.


In a further aspect of the present invention, the open-cell structure may have a plurality of voids which are substantially larger than the cells of the open-cell structure. The voids may be symmetrically positioned relative to an axis of symmetry in the membrane.


In still another aspect of the present invention, the open cell structure may have a natural, unbiased shape which is larger than the membrane. The open cell structure is compressed and positioned within the membrane so that the membrane holds the open cell structure in a collapsed shape.


The open cell structure may also include a channel extending along an outer surface of the open cell structure and adjacent to the inner surface of the membrane. The channel enhances fluid flow in this region and, in particular, in the area between the membrane and the open cell structure. The channels may be oriented radially with respect to an apex of the membrane, circumferentially or in any other suitable manner.


A plurality of spacers may also be used between the open cell structure and the membrane. The spacers provide an area between the membrane and the open cell structure which enhances fluid flow in the area between the membrane and open cell structure. The spacers may be attached to the external surface of the open cell structure or to the inner surface of the membrane.


The open cell structure may be selectively attached to the membrane at discrete locations which are separated by areas where the open cell structure is free to slide against the inner surface of the membrane. The attachments may be along the anterior wall and/or posterior wall so that portions of the anterior and/or posterior wall are free of attachments to the open cell structure. The attachments may be along a continuous strip of the membrane which, for example, forms a loops that encircles the apex of the membrane.


These and other features of the present invention will become apparent from the following description of the preferred embodiments.





BRIEF DESCRIPTION OF THE DRAWINGS


FIG. 1 shows an implantable prosthesis.



FIG. 2 is a top view of the implantable prosthesis of FIG. 1.



FIG. 3 shows an internal wall having an orifice.



FIG. 4 shows the internal wall in an expanded shape which reduces the size of the orifice.



FIG. 5 shows the internal wall separated from the rest of the prosthesis.



FIG. 6 shows the internal wall expanded to collapse the orifice.



FIG. 7 shows another implantable prosthesis having tension elements which may be selectively tensioned by the user.



FIG. 8 shows a plan view of the prosthesis of FIG. 7.



FIG. 9 shows another implantable prosthesis having tension members.



FIG. 10 shows a plan view of the prosthesis of FIG. 9.



FIG. 11 shows another implantable prosthesis having a chamber which may be filled or evacuated.



FIG. 12 shows the chamber of FIG. 11 expanded.



FIG. 13 is a plan view of the implantable prosthesis of FIG. 12.



FIG. 14 shows another implantable prosthesis.



FIG. 15 is a plan view of the implantable prosthesis of FIG. 14.



FIG. 16 shows an open cell structure.



FIG. 17 shows a membrane which is smaller than the open cell structure of FIG. 16.



FIG. 18 shows another implantable prosthesis.



FIG. 19 is a plan view of the implantable prosthesis of FIG. 18.



FIG. 20 shows still another implantable prosthesis having radially oriented channels.



FIG. 21 is a plan view of the implantable prosthesis of FIG. 20.



FIG. 22 shows another implantable prosthesis having circumferential channels.



FIG. 23 is a plan view of the implantable prosthesis of FIG. 22.



FIG. 24 shows still another implantable prosthesis with a circumferential channel.



FIG. 25 is a plan view of the implantable prosthesis of FIG. 24.



FIG. 26 shows another implantable prosthesis with a selective number of discrete attachments along the posterior and anterior walls.



FIG. 27 is a plan view of the prosthesis of FIG. 26.



FIG. 28 shows an implantable prosthesis which is attached to the membrane along two circular strips.



FIG. 29 is a plan view of the prosthesis of FIG. 28.



FIG. 30 shows a plurality of spacers positioned between the membrane and the open cell structure.



FIG. 31 shows another embodiment having a plurality of spacers.





DETAILED DESCRIPTION OF THE PREFERRED EMBODIMENT

Referring to FIGS. 1-6, an implantable prosthesis 2 is shown. The prosthesis 2 includes a membrane 4 which may be made formed in any suitable manner. The membrane 4 contains a flowable substance 6 such as silicone gel, saline or any other suitable substance. The flowable substance 6 may also include elements (not shown), such as beads or spheres, which are suspended in the flowable substance 6 without departing from the scope of the invention. Any of the embodiments disclosed herein may incorporate features, structures and materials disclosed in U.S. patent application Ser. No. 11/316,215 to Michael Lesh, entitled Tissue Augmentation Device filed Dec. 22, 2005, the disclosure of which is incorporated in its entirety herein by reference.


The membrane 4 is divided into a number of chambers 10 separated by walls 12. The walls 12 each have one or more orifices 14 which have a size which may be adjusted. Changing the size of the orifices 14 in the walls 12 alters the flow characteristics of the prosthesis 2 in that a smaller orifice 14 will provide a slower flow rate of the flowable substance 6 between the chambers 10. The chambers 10 may also be filled with a substance which further reduces the flow rate of fluid such as an open-cell structure which may be a matrix of material, a sponge, a foam or any other suitable open-cell structure which reduces the flow rate of fluid within the membrane 4 as described below in connection with other preferred embodiments.


The walls 12 include an inflatable element 18 which is inflated or deflated to change the size of the orifice 14. The inflatable element 18 may be formed by bonding two sheets of material 22 together to form the wall 12. The sheets 22 are bonded together around the orifices 14 and a hole is cut to form the orifice 14. Inflation of the space between the sheets 22 causes the inflatable element to expand thereby reducing the size of the orifice 14. A control element 24 is releasably coupled to the membrane 4 and is configured to extend out of the patient after the membrane 4 has been implanted into the patient. The control element 24 permits the user to change the size of the orifice 14 after introducing the prosthesis 2 into the patient. The control element 24 has a lumen coupled to a source of fluid (not shown) and may be provided with a releasable connection to the membrane 4 in any suitable manner. Although the control element 24 is configured to hydraulically alter the size of the orifice 14, the control element 24 may accomplish the change in orifice 14 size using any other method such as mechanical or electrical. For example, the size of the orifice 14 could be modified using a suture which cinches the orifice 14 to reduce the size of the orifice 14.


Referring to FIGS. 7 and 8, another implantable prosthesis 30 is shown. The prosthesis 30 includes a membrane 32 which holds the flowable substance 6. The membrane 32 may be filled with an open-cell structure 34 as described above. The prosthesis 30 also includes one or more tension elements 36 which extend between two portions of the wall of the membrane 32 to help maintain a more stable shape. The tension elements 36 may extend through a valve 38 in the prosthesis 30 which permits the tension element 36 to slide therethrough while still maintaining a fluid tight seal. The tension element 36 is coupled to a control element 40 which may simply be a portion of the tension element 36 which extends out of the prosthesis 30. The tension elements 36 may extend from a posterior wall 42 to an anterior wall 44 of the membrane 32 but may, of course, be coupled to other parts of the membrane 32 as well.


The control element 40 is configured to extend out of the patient when the prosthesis 30 is implanted so that the user may adjust tension on the tension element 36 after implantation. Tension may be applied to one or more of the tension elements 36 to create a desirable texture and feel to the prosthesis 30. After the desired tension has been applied, the control element 40 may be removed by simply cutting the control element 40 or releasing the control element 40 using any other suitable method. A locking element 43 is coupled to the membrane 32 which automatically secures the tension element 36 after tension has been increased with the control element 40. The control element 40 may, of course, be manipulated prior to implantation of the prosthesis 30.


Referring to FIGS. 9 and 10, still another implantable prosthesis 50 is shown. The prosthesis 50 includes a membrane 52 which holds the flowable substance 6. The membrane 52 may also contain an open-cell structure 56 which dampens fluid motion although the invention may be practiced without the open-cell structure 56. A plurality of tension members 58 extend through the open-cell structure 56 and are attached to the membrane 52 at both ends. The membrane 52 may have a round posterior wall 60 which is symmetrical about an axis of symmetry 62. The tension members 58 may extend from one side of the membrane 52 to a diametrically opposed side of the membrane 52. The tension members 58 may also be symmetrically arranged relative to the axis of symmetry 62 and may be coupled together at a junction 64 so that tension is distributed among the tension members 58.


Referring to FIGS. 11-13, yet another implantable prosthesis 70 is shown. The prosthesis 70 includes a membrane 72 having a first chamber 74, a second chamber 76 and a third chamber 78. The chambers 74, 76, 78 may be filled with an open-cell structure 80. The second chamber 76 is fluidly isolated from the first and third chambers 74, 78 and may be filled using a removable fill line 82. The second chamber 76 may be filled or evacuated as desired before or after the prosthesis 70 has been implanted into a patient. The second chamber 76 is positioned between the first and third chambers 74, 78 and may generally lie in a plane but may be oriented in any other suitable manner. The first and third chambers 74. 78 may be fluidly isolated from one another or may be fluidly coupled together.


Referring to FIGS. 14 and 15, another implantable prosthesis 84 is shown. The prosthesis includes a membrane 86 filled with the flowable substance 6. The prosthesis 84 also includes an open-cell structure 90 which dampens fluid motion and helps to maintain a desired shape. The open-cell structure 90 includes a plurality of voids 92 which are substantially larger than an average cell size in the open-cell structure 90. The membrane 86 may be symmetrical about an axis of symmetry 91 which is centrally located relative to a round posterior wall 94. The round posterior wall 94 and symmetrical shape permit the user to implant the device without requiring a particular orientation when implanted. The voids 92 are preferably symmetrically positioned relative to the axis of symmetry 91. The voids 92 may be elongate channels 96 cut into the open-cell structure 90 which extend from the posterior wall 94 to an anterior wall 95 of the prosthesis 84.


Referring again to FIGS. 1 and 9, a cover 96 may be used to cover a portion of an outer surface 99 of the membrane 4 and may be used with any of the implants described herein. The cover 96 may be a strip 98 of expanded PTFE which extends over, and essentially parallel to, an area commonly referred to as the waist 100. The waist 100 is generally defined as a radially outer portion of the membrane 52 when the membrane 52 is supported by the posterior wall 60 as shown in FIG. 9. The cover 96 is positioned so that at least 80% of the ePTFE is positioned no more than 1 cm from the waist 100. Positioning the ePTFE cover 96 in this manner provides the advantages of ePTFE, such as the promotion of in-growth, without the high cost of covering the entire implant with ePTFE as has been suggested by some prior art devices. Of course, numerous aspects of the present invention may be practiced without the cover 96 or with the cover 96 extending around the entire outer surface or a substantial portion thereof without departing from those aspects of the invention.


The cover 96 may be applied to the membrane 52 in the following manner when using the strip 98 of ePTFE. The membrane 52 is held at two spaced-apart locations 103, 105 along the waist 100 and the membrane 52 is stretched to increase the space between these locations. The membrane 52 may be held by a curved work element which supports the curved shape of the membrane when the membrane 52 is stretched. The strip 98 is then attached to the membrane at both locations 103, 105 and the membrane 52 is then released to release tension on the membrane 52. This process may be repeated until the entire waist 100 is covered by the strip 98. In one embodiment, the strip 98 is attached at 6-10 locations around the periphery of the waist 100.


Referring now to FIGS. 16 and 17, still another aspect of the present invention is shown. An open cell structure 102 is provided which has a natural, unbiased shape which is larger than membrane 104. The open cell structure 102 is compressed within the membrane 104 which holds the open cell structure 102 in a compressed state. The open cell structure 102 may occupy a volume when in the natural unbiased shape which is 5% to 20% larger than the volume of the membrane 104.


The open cell structure 102 may be larger than the membrane 104 in all dimensions or may be selectively larger in one or more dimensions. For example, the open cell structure 100 may have a height H which is 5% to 20% larger than a maximum dimension between an anterior wall 106 and a posterior wall 108. The open cell structure 102 may also have a width W which is 5% to 20% larger than a maximum outer dimension or diameter of the posterior wall 108.


Referring now to FIGS. 18-25, an implantable prosthesis 109 is shown which has a membrane 110 and an open cell structure 114 with channels 122 formed in an outer surface 124 of the open cell structure 114. The membrane 110 includes a posterior wall 116 and an anterior wall 118 having an apex 120. The channels 122 may be positioned adjacent to an inner surface 126 of the membrane 110 so that the flowable substance can flow in a more unrestricted manner in the channels 122 than in the open cell structure 114. The channels 122 may extend radially relative to the apex 120 of the membrane 112 (FIGS. 18-21). The channels 120 may intersect one another at the inner surface 126 of the membrane 112 below the apex 120 (FIGS. 20 and 21) or may be non-intersecting (FIGS. 18 and 19). Referring to FIGS. 22 and 23, the channel 122 may also extend circumferentially about the outer surface 124 of the open cell structure 114. The channel 122 may also be positioned adjacent to a waist 128 of the membrane which is a radially outer portion of the membrane 110 near the posterior wall 116 as described above. The channel 122 may also extend around the apex 120 of the membrane 110 at a position nearer to the apex 120 than to the waist 128 as shown in FIGS. 24 and 25.


Referring now to FIGS. 26-29, open cell structure 130 may be attached to membrane 132 at a selective number of locations which are separated by portions of the open cell structure 130 which are free to move relative to an inner surface 134 of the membrane 132. FIGS. 26 and 27 shows the open cell structure 130 attached to the membrane 132 at four spaced apart locations on anterior wall 136 and posterior wall 138. FIGS. 28 and 29 show the open cell structure 130 attached to the membrane 132 along a strip 140 on the anterior wall 136 and along a strip 142 on the posterior wall 138. The strip 136 on the anterior wall 136 may form a closed loop that encircles the apex of the membrane.


Referring now to FIGS. 30 and 31, spacers 144 may also be provided between open cell structure 146 and the membrane 148. The spacers 144 create an area between the membrane 148 and the open cell structure 146 so that the flowable substance may flow in a less restricted manner in this area as compared to within the open cell structure 146. The spacers 144 may be attached to the membrane 148 or to the open cell structure 146 and may be integrally formed with either part. When attached to the open cell structure 146, the spacers 144 are free to slide against an inner surface 150 of the membrane 148. The spacers 144 may be sized and positioned so that less than 20% of an outer surface 152 of the open cell structure 146 is covered by the spacers 144. Stated another way, at least 80% of the outer surface 152 of the open cell structure 146 is free to move relative to the inner surface 150 of the membrane 148. The spacers 144 may be arranged in a radially oriented fashion (FIG. 30) or in a circumferential pattern (FIG. 31) or any other suitable configuration without departing from the scope of the invention.


The present invention has been described in connection with various preferred embodiments and it is understood that modifications and alterations of these embodiments may be accomplished while remaining within the scope of the invention as defined by the claims. For example, the implants may be anatomical implants rather than symmetrical implants without departing from the scope of various aspects of the invention. Furthermore, the various aspects of the invention have been described independently but may, of course, be practiced together and such combinations are expressly incorporated. For example, the spacers 144 of FIGS. 30 and 31 could be used in combination with the tension elements 36 of FIGS. 7 and 8.

Claims
  • 1. An implantable breast prosthesis, comprising: a soft, flexible outer membrane comprising a convex anterior wall and a flat posterior wall, the membrane having a volume, a maximum height, and a maximum diameter of the posterior wall;a flowable substance contained within the membrane and configured to flow within the membrane, wherein the flowable substance comprises saline or water; andan open cell structure positioned inside the membrane, the open cell structure being filled with the flowable substance so that the open cell structure dampens motion of the flowable substance within the membrane,wherein the open cell structure has a natural, unbiased shape when not positioned inside the membrane, the natural, unbiased shape being larger than the membrane,the membrane holding the open cell structure in a compressed state when the open cell structure is positioned inside the membrane, the compressed state being smaller than the natural, unbiased shape, andwherein the open cell structure has a volume in its natural, unbiased shape that is 5% to 20% larger than the volume of the membrane, andwherein the natural, unbiased shape of the open cell structure has at least one of (1) a height which is 5% to 20% larger than the maximum height of the membrane and (2) a diameter which is 5% to 20% larder than the maximum diameter of the posterior wall.
  • 2. The implantable breast prosthesis, of claim 1, further comprising: a tension element coupled to the membrane at a first location and a second location; and a control element coupled to the tension element, the control element being configured to increase tension on the tension element so that the tension element draws the first and second locations toward one another.
  • 3. The implantable breast prosthesis of claim 2, wherein the control element is configured to extend out of a patient when the membrane has been implanted into the patient so that tension on the tension element may be altered after the membrane has been implanted into the patient.
  • 4. The implantable breast prosthesis of claim 2, wherein the first location being on the posterior wall and the second location being on the anterior wall.
  • 5. The implantable breast prosthesis of claim 2, further comprising a plurality of tension elements extending within the membrane, each of the tension elements being configured to be tensioned independently by a user after introduction of the membrane into the patient.
  • 6. The implantable breast prosthesis of claim 1, further comprising a plurality of elastic tension elements extending through the open-cell structure coupled to the membrane, each tension element having a first end and a second end which are both attached to the membrane.
  • 7. The implantable breast prosthesis of claim 1, further comprising a plurality of voids in the open-cell structure which are substantially larger than the cells of the open-cell structure.
  • 8. The implantable breast prosthesis of claim 7, wherein the plurality of voids are organized in a symmetrical pattern relative to an axis of symmetry.
  • 9. The implantable breast prosthesis of claim 7, wherein the plurality of voids are elongate channels which extend through the open-cell structure.
  • 10. The implantable breast prosthesis of claim 1, further comprising a cover material; the membrane having an outer surface and a waist, the waist being an outer ring which is positioned between the anterior wall and the posterior wall when the membrane is supported by the posterior wall;the cover material extending over the membrane and being made of expanded PTFE, wherein at least 80 percent of the expanded PTFE which covers the membrane is positioned no more than one centimeter from the waist of the membrane.
  • 11. The implantable breast prosthesis of claim 10, wherein the outer surface of the membrane is exposed to tissue when implanted into a patient except for the portion of the outer surface covered by the cover material.
  • 12. The implantable breast prosthesis of claim 10, wherein the cover material is a strip which wraps around the membrane in a direction which is parallel to the waist so that the strip covers the outer surface of the membrane along the waist.
  • 13. The implantable breast prosthesis of claim 1, wherein the membrane includes an inner surface which is exposed to the flowable substance; and the open cell structure includes a channel extending along an outer surface of the open cell structure adjacent to the inner surface of the membrane.
  • 14. The implantable breast prosthesis of claim 13, wherein the anterior wall has an apex; and the open cell structure includes a plurality of channels which intersect along the inner surface of the membrane below the apex.
  • 15. An implantable prosthesis, comprising: a soft, flexible outer membrane, the membrane having a volume, a maximum height, an outer surface, a posterior wall, an anterior wall, and a waist, the waist being an outer ring portion of the membrane which is positioned between the anterior wall and the posterior wall when the membrane is supported by the posterior wall, the membrane having a maximum diameter at the waist when the membrane is supported by the posterior wall;a flowable substance contained within the membrane and configured to flow within the membrane, wherein the flowable substance comprises saline or water;an open cell structure positioned inside the membrane, the open cell structure being filled with the flowable substance so that the open cell structure dampens motion of the flowable substance within the membrane; anda cover material, the cover material extending over the waist of the membrane and being made of expanded PTFE, wherein at least 80 percent of the expanded PTFE is positioned no more than one centimeter from the waist of the membrane;wherein the open cell structure has a natural, unbiased shape when not positioned inside the membrane, the natural, unbiased shape being larger than the membrane,the membrane holding the open cell structure in a compressed state when the open cell structure is positioned inside the membrane, the compressed state being smaller than the natural, unbiased shape, andwherein the open cell structure has a volume in its natural, unbiased shape that is 5% to 20% larger than the volume of the membrane, andwherein the natural, unbiased shape of the open cell structure has at least one of (1) a height which is 5% to 20% larger than the maximum height of the membrane and (2) a diameter which is 5% to 20% larder than a maximum outer diameter of the posterior wall.
CROSS-REFERENCE TO RELATED APPLICATIONS

The present application is a continuation application of U.S. patent application Ser. No. 12/024,835 filed Feb. 1, 2008, which is hereby incorporated by reference herein in its entirety.

US Referenced Citations (226)
Number Name Date Kind
2512568 Saffir Jun 1950 A
3293663 Cronin Dec 1966 A
3366975 Pangman Feb 1968 A
3919724 Sanders et al. Nov 1975 A
3934274 Hartley, Jr. et al. Jan 1976 A
3949073 Daniels et al. Apr 1976 A
3953566 Gore Apr 1976 A
4051840 Kantrowitz et al. Oct 1977 A
4187390 Gore Feb 1980 A
4327734 White, Jr. May 1982 A
4383929 Bertocchio May 1983 A
4395806 Wonder et al. Aug 1983 A
4433440 Cohen Feb 1984 A
4517979 Pecenka May 1985 A
4531244 Hamas Jul 1985 A
4543088 Bootman Sep 1985 A
4545367 Tucci Oct 1985 A
4592755 Penton et al. Jun 1986 A
4631188 Stoy et al. Dec 1986 A
4643733 Becker Feb 1987 A
4648880 Brauman Mar 1987 A
4664655 Orentreich et al. May 1987 A
4738657 Hancock Apr 1988 A
4820303 Brauman Apr 1989 A
4828561 Woodroof May 1989 A
4828827 Henderson et al. May 1989 A
4840615 Hancock Jun 1989 A
4863470 Carter Sep 1989 A
4904260 Ray et al. Feb 1990 A
4908029 Bark Mar 1990 A
4917646 Kieves Apr 1990 A
4944749 Becker Jul 1990 A
4955907 Ledergerber Sep 1990 A
4963150 Brauman Oct 1990 A
4966478 Kuo Oct 1990 A
4969901 Binder Nov 1990 A
4994028 Leonard et al. Feb 1991 A
5007929 Quaid Apr 1991 A
5019101 Purkait et al. May 1991 A
5074878 Bark et al. Dec 1991 A
5098779 Kranzler et al. Mar 1992 A
5102389 Hauser Apr 1992 A
5116387 Berg May 1992 A
5123905 Kelman Jun 1992 A
5141508 Bark et al. Aug 1992 A
5181921 Makita et al. Jan 1993 A
5188558 Barton et al. Feb 1993 A
5213574 Tucker May 1993 A
5273532 Niezink et al. Dec 1993 A
5282856 Ledergerber Feb 1994 A
5324259 Taylor et al. Jun 1994 A
5356429 Seare Oct 1994 A
5376117 Pinchuk et al. Dec 1994 A
5387192 Glantz Feb 1995 A
5425747 Brotz Jun 1995 A
5425760 Rosenberg Jun 1995 A
5437900 Kuzowski Aug 1995 A
5454788 Walker et al. Oct 1995 A
5456716 Iverson et al. Oct 1995 A
5461781 Zukoski Oct 1995 A
5480430 Carlisle Jan 1996 A
5496345 Kieturakis et al. Mar 1996 A
5496367 Fisher Mar 1996 A
5496370 Hamas Mar 1996 A
5514153 Bonutti May 1996 A
5545217 Offray et al. Aug 1996 A
5545220 Andrews et al. Aug 1996 A
5549672 Maddock et al. Aug 1996 A
5558641 Glantz Sep 1996 A
5558829 Petrick Sep 1996 A
5571189 Kuslich Nov 1996 A
RE35391 Brauman Dec 1996 E
5582585 Nash-Morgan Dec 1996 A
5584859 Brotz Dec 1996 A
5599852 Scopelianos et al. Feb 1997 A
5607477 Schindler et al. Mar 1997 A
5630843 Rosenberg May 1997 A
5630844 Dogan et al. May 1997 A
5632777 Petrick May 1997 A
5633001 Agerup May 1997 A
5643783 Olsen et al. Jul 1997 A
5645081 â„«rgenta et al. Jul 1997 A
5645558 Horton Jul 1997 A
5645597 Krapiva Jul 1997 A
5653755 Ledergerber Aug 1997 A
5653757 Petrick Aug 1997 A
5658330 Carlisle et al. Aug 1997 A
5660849 Polson et al. Aug 1997 A
5674285 Quaid Oct 1997 A
5702677 Shimp et al. Dec 1997 A
5725507 Petrick Mar 1998 A
5728752 Scopelianos et al. Mar 1998 A
5779672 Dormandy, Jr. Jul 1998 A
5779734 Ledergerber Jul 1998 A
5782913 Schindler et al. Jul 1998 A
5795325 Valley et al. Aug 1998 A
5798096 Pavlyk Aug 1998 A
5824081 Knapp et al. Oct 1998 A
5861032 Subramaniam Jan 1999 A
5863297 Walter et al. Jan 1999 A
5871537 Holman et al. Feb 1999 A
5922025 Hubbard Jul 1999 A
5931855 Buncke Aug 1999 A
5935164 Iversen Aug 1999 A
5935362 Petrick Aug 1999 A
5941910 Schindler et al. Aug 1999 A
5944738 Amplatz et al. Aug 1999 A
D413672 Fogarty Sep 1999 S
5957939 Heaven et al. Sep 1999 A
5961552 Iversen et al. Oct 1999 A
5964261 Neuenfeldt et al. Oct 1999 A
5964803 Iversen Oct 1999 A
5984943 Young Nov 1999 A
5989214 van de Wijdeven Nov 1999 A
5989216 Johnson Nov 1999 A
5997574 Hayes et al. Dec 1999 A
6039712 Fogarty Mar 2000 A
6053899 Slanda et al. Apr 2000 A
6060639 Petrick May 2000 A
6090063 Makower et al. Jul 2000 A
6098629 Johnson et al. Aug 2000 A
6146418 Berman Nov 2000 A
6162251 Kredovski Dec 2000 A
6171298 Matsuura et al. Jan 2001 B1
6187043 Ledergerber Feb 2001 B1
6214045 Corbitt, Jr. et al. Apr 2001 B1
6228116 Ledergerber May 2001 B1
6231586 Mariant May 2001 B1
6231613 Greff et al. May 2001 B1
6241747 Ruff Jun 2001 B1
6251137 Andrews et al. Jun 2001 B1
6258055 McCrory et al. Jul 2001 B1
6261316 Shaolian et al. Jul 2001 B1
6261323 Neto Jul 2001 B1
6264700 Kilcoyne et al. Jul 2001 B1
6267772 Mulhauser et al. Jul 2001 B1
6270517 Brotz Aug 2001 B1
6277150 Crawley et al. Aug 2001 B1
6296624 Gerber et al. Oct 2001 B1
6299590 Luscher et al. Oct 2001 B1
6312405 Meyer et al. Nov 2001 B1
6315796 Eaton Nov 2001 B1
6322576 Wallace et al. Nov 2001 B1
6379329 Naglreiter et al. Apr 2002 B1
6402784 Wardlaw Jun 2002 B1
6440098 Luscher Aug 2002 B1
6451052 Burmeister et al. Sep 2002 B1
6458119 Berenstein et al. Oct 2002 B1
6470216 Knowlton Oct 2002 B1
6471689 Joseph et al. Oct 2002 B1
6478656 Khouri Nov 2002 B1
6478809 Brotz Nov 2002 B1
RE37950 Dunn et al. Dec 2002 E
6520989 Eaton Feb 2003 B1
6530896 Elliott Mar 2003 B1
6537242 Palmer Mar 2003 B1
6544287 Johnson et al. Apr 2003 B1
6551342 Shen et al. Apr 2003 B1
6578580 Conrad et al. Jun 2003 B2
6585748 Jeffree Jul 2003 B1
6599310 Leung et al. Jul 2003 B2
6629947 Sahatjian et al. Oct 2003 B1
6648853 McEntee Nov 2003 B1
6652544 Houser et al. Nov 2003 B2
6660301 Vogel et al. Dec 2003 B1
6663596 Griego et al. Dec 2003 B2
6673105 Chen Jan 2004 B1
6684107 Binder Jan 2004 B1
6699176 Khouri Mar 2004 B1
6702731 Milbocker Mar 2004 B2
6716251 Asius et al. Apr 2004 B1
6725866 Johnson et al. Apr 2004 B2
6740082 Shadduck May 2004 B2
6743208 Coyle Jun 2004 B1
6755861 Nakao Jun 2004 B2
6802861 Hamas Oct 2004 B1
6878137 Benchetrit Apr 2005 B2
6899713 Shaolian et al. May 2005 B2
6921418 Ledergerber Jul 2005 B2
7077865 Bao et al. Jul 2006 B2
7094230 Flaherty et al. Aug 2006 B2
7244270 Lesh Jul 2007 B2
7641688 Lesh Jan 2010 B2
7758649 Walsh et al. Jul 2010 B2
7998201 Lesh Aug 2011 B2
7998202 Lesh Aug 2011 B2
8556968 Hamas et al. Oct 2013 B2
20020019670 Crawley et al. Feb 2002 A1
20020022861 Jacobs et al. Feb 2002 A1
20020025340 Dyer Feb 2002 A1
20030028147 Aves et al. Feb 2003 A1
20030074021 Morriss et al. Apr 2003 A1
20030074084 Nakao Apr 2003 A1
20030225453 Murch Dec 2003 A1
20040037887 Bourne et al. Feb 2004 A1
20040176841 Ferguson Sep 2004 A1
20040243157 Connor et al. Dec 2004 A1
20040249457 Smith et al. Dec 2004 A1
20050131325 Chen et al. Jun 2005 A1
20050177234 Raphael Aug 2005 A1
20050187624 Corbitt, Jr. Aug 2005 A1
20060058735 Lesh Mar 2006 A1
20060058890 Lesh Mar 2006 A1
20060058891 Lesh Mar 2006 A1
20060058892 Lesh Mar 2006 A1
20060136070 Pinchuk Jun 2006 A1
20060161253 Lesh Jul 2006 A1
20060282164 Seastrom Dec 2006 A1
20080015498 Lesh Jan 2008 A1
20080221678 Hamas Sep 2008 A1
20080221679 Hamas Sep 2008 A1
20080275569 Lesh Nov 2008 A1
20090024215 Lesh Jan 2009 A1
20090024227 Lesh Jan 2009 A1
20090024228 Lesh Jan 2009 A1
20090048684 Lesh Feb 2009 A1
20090125107 Maxwell May 2009 A1
20090149953 Schuessler et al. Jun 2009 A1
20090198328 Kesten et al. Aug 2009 A1
20090198330 Kesten et al. Aug 2009 A1
20090198331 Kesten et al. Aug 2009 A1
20100087922 Hamas Apr 2010 A1
20100133133 Hamas Jun 2010 A1
20100249946 Lesh et al. Sep 2010 A1
20100249947 Lesh et al. Sep 2010 A1
20140163696 Lesh et al. Jun 2014 A1
Foreign Referenced Citations (8)
Number Date Country
0322194 Jun 1989 EP
0357927 Mar 1990 EP
0411767 Mar 1991 EP
2 158 552 Nov 2000 RU
WO 9522359 Aug 1995 WO
WO 9611647 Apr 1996 WO
WO 9837836 Sep 1998 WO
WO 9917816 Apr 1999 WO
Non-Patent Literature Citations (4)
Entry
International Search Report and Written Opinion of the International Searching Authority for International Application No. PCT/US2009/032259, mailed on Mar. 16, 2009, in 14 pages.
Homicz, Mark R., M.D. et al., Review of Injectable Materials for Soft Tissue Augmentation, Facial Plastic Surgery, vol. 20, No. 1, 2004.
Sciafani, Anthony P. et al., Collagen, Human Collagen, and Fat: The Search for a Three-Dimensional Soft Tissue Filler, Facial Plastic Surgery, vol. 17, No. 1, 2001.
Wall, Stephen J., M.D., Ph.D. et al., Patient Satisfaction with Expanded Polytetrafluoroethylene (Softform) Implants to the Perioral Region, Arch Facial Plast Surg. vol. 5, Jul./Aug. 2003.
Related Publications (1)
Number Date Country
20140135923 A1 May 2014 US
Continuations (1)
Number Date Country
Parent 12024835 Feb 2008 US
Child 14042457 US